> A new report from BCC Research concludes that the CNS biomarker market, worth $2 billion in 2012, will grow to $5.1 billion in 2017. Factors driving that growth include an aging population alongside the growth of new public/private partnerships. Release
> Empire Genomics has grabbed a license for a biomarker that could be used to develop a new diagnostic test for neuroendocrine prostate cancer. Empire did the deal with Cornell. Report
> Medical researchers at the University of Alberta have pinpointed a genetic marker for sporadic breast cancer--one of a handful identified to date in Caucasians. Release